

Topical Collection

Multiple Myeloma and Cellular Therapies

Message from the Collection Editor

Although the introduction of innovative drug therapies has led to the improvement of median overall survival from 3 to 6–7 years in the last 2 decades, multiple myeloma (MM) remains an incurable disease. In this Topical Collection, we will focus on the following items: (1) high dose therapy followed by the reinfusion of autologous stem cells is the “gold standard” for newly diagnosed MM; however, the eligibility of elderly patients, new conditioning regimens, and novel drugs before and after autologous transplant are areas of current active investigation; (2) allogeneic stem cell transplantation can be reserved to fit patients with very high-risk MM, but transplant indications and strategies to reduce transplant-related mortality and the relapse risk are controversial; (3) chimeric antigen receptor (CAR) T cell therapy directed to B cell maturation antigen (BCMA) is the most innovative treatment for relapsed and refractory disease with several phase II and III studies recruiting worldwide, and with ongoing basic research aiming to improve T cell engineering and persistence. We look forward to your contributions.

Collection Editor

Dr. Francesca Patriarca

1. Clinica Ematologica e Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy
2. Dipartimento di Area Medica, Università di Udine, 33100 Udine, Italy



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/76245

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/cells)

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).